



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyyssw@sina.com

产品名称: **Azelastine**
CAS 号: **58581-89-8**
产品货号: **S80815**

生物活性:				
Description	Azelastine 属于抗组胺剂，是一种有效的选择性组胺 1 (H1) 拮抗剂。Azelastine 可用于过敏性鼻炎、哮喘、糖尿病高脂血症和 SARS-CoV-2 的研究。			
IC50 & Target[1]	H1 Receptor			
Cellular Effect	Cell Line	Type	Value	Description
	Ventricular myocyte	IC ₅₀	20.2 μM	Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes
In Vitro	Azelastine can significantly inhibit HNEpC proliferation, and therefore, be helpful in against airway remodeling[5].			
	Cell Proliferation Assay[5]			
	Cell Line:		Human nasal epithelial cells (HNEpC)	
	Concentration:		100 μM, 400 μM	
	Incubation Time:		21 days	
	Result:		Inhibited HNEpC growth.	
	Western Blot Analysis[5]			
	Cell Line:		Human nasal epithelial cells (HNEpC)	
	Concentration:		100 μM	
	Incubation Time:		7 days	
	Result:		Significantly up-regulated the H1R, M1R and M3R levels.	
In Vivo	Azelastine (4 mg/kg; p.o.; daily; for 8 weeks) significantly reduces blood glucose, HbA1c and serum alkaline phosphatase (ALP), osteocalcin and downregulates apolipoprotein B in diabetic hyperlipidemic rats model[2].			
	Azelastine (4 mg/kg; p.o.; daily; for 8 weeks) improves the lipid profile (LDL-c decrease and HDL-c increase) in diabetic hyperlipidemic rats model[2].			
	Azelastine (4 mg/kg; p.o.; daily; for 8 weeks) attenuates calcium deposition and aortic calcification in diabetic hyperlipidemic rats model[2].			
	Animal Model:		Male albino Wistar rats (150-170 g), diabetic hyperlipidemic rats model[2]	
	Dosage:		4 mg/kg	
	Administration:		Oral administration, daily, for 8 weeks	
	Result:		Ameliorated aortic calcification and increased apolipoprotein A expression along with a decline in apolipoprotein B.	
参考文献	[1]. Craig La Force. Review of the pharmacology, clinical efficacy, and safety of azelastine hydrochloridel. Expert Rev Clin Immunol. 2005 Jul;1(2):191-201. [2]. Mohamed M Elseweidy, et al. Azelastine a potent antihistamine agent, as hypolipidemic and modulator for aortic calcification in diabetic hyperlipidemic rats model. Arch Physiol Biochem. 2020 Jul 2;1-8. [3]. Carlos D. Zappia, et al. Azelastine potentiates antiasthmatic dexamethasone effect on a murine asthma model. Pharmacol Res Perspect. 2019 Dec; 7(6): e00531. [4]. Li Yang, et al. Identification of SARS-CoV-2 entry inhibitors among already approved drugs. Acta Pharmacol Sin. 2020 Oct 28 : 1-7.			



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

	[5]. Shao-Cheng Liu, et al. Effect of budesonide and azelastine on histamine signaling regulation in human nasal epithelial cells. Eur Arch Otorhinolaryngol. 2017 Feb;274(2):845-853.
--	--



源叶